🌍·Jan 1, 1970Industry
2026/05/11 公司新闻 华东医药独家商业化Ⅱ代高选择性JAK1抑制剂VC005片中重度特应性皮炎Ⅲ期临床取得积极顶线数据
Publisher
H
Huadong Medicine
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Huadong Medicine
- Region
- 最新
- Scope
- Industry
- Published
- January 1, 1970
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on eastchinapharm.com
Leave the platform to read the original full article on the publisher site.
Source: Huadong Medicine
Scope: Industry
Related coverage
More related coverage
Certara·16h ago
Certara Integrates D360™ with Secondary Intelligence™ Software to Enhance Predicting Drug Safety Risk
GSK News·17h ago
GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome
AbbVie News·22h ago
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
UC Davis Health·22h ago